Table 2.

ERG-positive and ERG-negative incident prostate cancer by aspirin use (fully adjusted model^a)

	No. of cases		HR (95% CI)
	ERG-positive	ERG-negative
Total	439	473	ERG-positive	ERG-negative
Categories of use
Never user	147	138	1 (ref)	1 (ref)
Past user	107	114	1.02 (0.79–1.31)	1.04 (0.82–1.33)
Current user	185	221	1.03 (0.83–1.28)	1.11 (0.89–1.37)
			P_{heterogeneity} = 0.88
Current use
Never/past user	254	252	1 (ref)	1 (ref)
Current user	185	221	1.02 (0.85–1.23)	1.09 (0.91–1.30)
			P_{heterogeneity} = 0.63
Ever use
Never user	147	138	1 (ref)	1 (ref)
Ever user	292	335	1.03 (0.84–1.25)	1.08 (0.89–1.33)
			P_{heterogeneity} = 0.69
Duration of use since baseline
Non-aspirin user	147	138	1 (ref)	1 (ref)
Aspirin use <5 years	134	149	1.00 (0.79–1.26)	1.17 (0.94–1.46)
Aspirin use 5–<10 years	90	92	1.11 (0.85–1.44)	0.98 (0.76–1.28)
Aspirin use 10 years+	68	94	0.96 (0.71–1.30)	1.03 (0.77–1.37)
			P_{heterogeneity} = 0.48
Per year of use	439	473	1.00 (1.00–1.00)	1.00 (1.00–1.00)
			P_{heterogeneity} = 0.62
Frequency of use
Aspirin use <2 d/wk (never/past user)	254	252	1 (ref)	1 (ref)
Aspirin use 2–<6 d/wk	72	81	0.94 (0.73–1.21)	1.05 (0.83–1.33)
Aspirin use 6+ d/wk	113	140	1.09 (0.87–1.37)	1.12 (0.90–1.39)
			P_{heterogeneity} = 0.82
Per d/wk of use	439	473	1.02 (0.98–1.05)	1.01 (0.98–1.05)
			P_{heterogeneity} = 0.93

Abbreviation: ref, reference category.
↵^aAdjusted for age, calendar time, race (Caucasian, other), family history of prostate cancer in father or brother (yes, no), height (≤68, >68–70, >70–72, >72 inches), body mass index (<21, 21–<25, 25–<30, 30+ kg/m²), body mass index at age 21 years (<20, 21–<25, 25–<30, 30+ kg/m²), physical activity (quintiles of metabolic equivalents-hours/week), smoking (never, former/quit >10 years ago, former/quit ≤10 years ago, current), history of diabetes (yes, no), time-varying current statin use (yes, no), PSA testing in the 2 years prior to the questionnaire date (yes, no; lagged by one period to avoid counting diagnostic PSA tests as screening), and PSA testing in >50% of possible time periods (yes, no; lagged by one period to avoid counting diagnostic PSA tests as screening).